General Information of Drug (ID: DMZ8PY0)

Drug Name
ACE-031 Drug Info
Indication
Disease Entry ICD 11 Status REF
Duchenne dystrophy 8C70 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMZ8PY0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2495655 DMM5JAN Disuse muscle atrophy 8B61 Phase 2 [3]
AMG 745 DMFXN2T Muscle atrophy FB32.Y Phase 2 [4]
PF-06252616 DMQLZOF Duchenne dystrophy 8C70 Phase 2 [3]
SAR391786 DMS1YPZ Muscle atrophy FB32.Y Phase 2 [5]
Domagrozumab DMCT08V Duchenne dystrophy 8C70 Phase 2 [6]
Stamulumab DMBCIXL Duchenne dystrophy 8C70 Phase 1/2 [3]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Growth/differentiation factor 8 (GDF-8) TTSWPH8 GDF8_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT01099761) Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy. U.S. National Institutes of Health.
2 A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23.
3 Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.
4 The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011 September; 2(3): 143-151.
5 Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar;10(1):56-63.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)